ABCB1 C3435T, G2677T/A and C1236T variants have no effect in eslicarbazepine pharmacokinetics

Simple item page
dc.centroUniversidad San Pablo-CEU
dc.contributor.authorPeso-Casado, Miriam del
dc.contributor.authorOchoa Mazarro, Dolores
dc.contributor.authorEnrique-Benedito, Teresa
dc.contributor.authorMejía-Abril, Gina
dc.contributor.authorNavares, Marcos
dc.contributor.authorVillapalos-García, Gonzalo
dc.contributor.authorRomán, Manuel
dc.contributor.authorAbad-Santos, Francisco
dc.contributor.authorZubiaur, Pablo
dc.contributor.authorOvejero Benito, María del Carmen
dc.contributor.otherUniversidad San Pablo-CEU. Facultad de Farmacia. Departamento de Ciencias Farmacéuticas y de la Salud
dc.contributor.otherHospital Universitario de la Princesa
dc.contributor.otherInstituto de Investigación Sanitaria la Princesa
dc.date2021
dc.date.accessioned2024-01-10T12:36:23Z
dc.date.available2024-01-10T12:36:23Z
dc.date.issued2021-10-01
dc.descriptionEslicarbazepine acetate is a third-generation anti-epileptic prodrug quickly and extensively transformed to eslicarbazepine after oral administration. Reduction in seizure frequency in patients managed with eslicarbazepine is only partial in the majority of patients and many of them suffer considerable ADRs that require a change of treatment. The P-glycoprotein, encoded by the ABCB1 gene, is expressed throughout the body and can impact the pharmacokinetics of several drugs. In terms of epilepsy treatment, this transporter was linked to drugresistant epilepsy, as it conditions drug access into the brain due to its expression at the blood-brain barrier. Therefore, we aimed to investigate the impact of three ABCB1 common polymorphisms (i.e., C3435T, or rs1045642, G2677A or rs2032582 and C1236T or rs1128503) in the pharmacokinetics and safety of eslicarbazepine. For this purpose, 22 healthy volunteers participating in a bioequivalence clinical trial were recruited. No significant relationship was observed between sex, race and ABCB1 polymorphism and eslicarbazepine pharmacokinetic variability. In contrast, ABCB1 C1236T C/C diplotype was significantly related to the occurrence of ADRs: one volunteer with this genotype suffered dizziness, somnolence and hand paresthesia, while no other volunteer suffered any of these ADRs (p < 0.045). To the best of our knowledge, this is the first study published to date evaluating eslicarbazepine pharmacogenetics. Further studies with large sample sizes are needed to compare the results obtained here.en_EN
dc.identifier.citationPablo Zubiaur, Miriam del Peso-Casado, Dolores Ochoa, Teresa Enrique-Benedito, Gina Mejía-Abril, Marcos Navares, Gonzalo Villapalos-García, Manuel Román, Francisco Abad-Santos, María Carmen Ovejero-Benito, ABCB1 C3435T, G2677T/A and C1236T variants have no effect in eslicarbazepine pharmacokinetics, Biomedicine & Pharmacotherapy, Volume 142, 2021, 112083, ISSN 0753-3322, https://doi.org/10.1016/j.biopha.2021.112083.
dc.identifier.doi10.1016/j.biopha.2021.112083
dc.identifier.issn1950-6007
dc.identifier.urihttp://hdl.handle.net/10637/14765
dc.language.isoen
dc.publisherElselvier
dc.relation.ispartofBiomedicine & Pharmacotherapy
dc.rightsopen access
dc.rights.cchttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subjectPharmacogeneticsen_EN
dc.subjectAnti-epileptic drugsen_EN
dc.titleABCB1 C3435T, G2677T/A and C1236T variants have no effect in eslicarbazepine pharmacokineticsen_EN
dc.typeArtículo
dspace.entity.typePublicationes
relation.isAuthorOfPublication95639da1-55e7-4f9c-9f67-28676cc5aca2
relation.isAuthorOfPublication.latestForDiscovery95639da1-55e7-4f9c-9f67-28676cc5aca2

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
ABCB1_Zubiaur_et_al_Bio_Phar_2021.pdf
Size:
392.54 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Facultad de Farmacia
x

The user has the obligation to use the services and content provided by the University, in particular, printed and electronic resources, in accordance with current legislation and the principles of good faith and generally accepted uses, without contravening with its performance the public order, especially, in the case in which, for the adequate performance of its activity, it needs to reproduce, distribute, communicate and/or make available, fragments of printed works or capable of being in analog or digital format, either on paper or electronic support. Law 23/2006, of July 7, which modifies the revised text of the Intellectual Property Law, approved by Royal Legislative Decree 1/1996, of April 12. B.O.E. n 162, of July 8, and concordant regulations.

@ 2024 Fundación Universitaria San Pablo CEU (Madrid). All rights reserved.

DSpace Software Copyright © 2002-2013 Duraspace